Updates are available Correction dated 2024-10-10
Click to view Correction: https://doi.org/10.1038/s41467-024-52861-x
-
Authors
Darragh, Laurel B. https://orcid.org/0000-0002-6445-7988
Gadwa, Jacob
Pham, Tiffany T.
Van Court, Benjamin
Neupert, Brooke
Olimpo, Nicholas A.
Nguyen, Khoa
Nguyen, Diemmy
Knitz, Michael W. https://orcid.org/0000-0002-5786-9837
Hoen, Maureen
Corbo, Sophia
Joshi, Molishree
Zhuang, Yonghua
Amann, Maria
Wang, Xiao-Jing https://orcid.org/0000-0001-8695-7361
Dow, Steven
Kedl, Ross M.
Samedi, Von
Boss, Mary-Keara
Karam, Sana D. https://orcid.org/0000-0003-1676-5967
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (F31 DE029997, DE028529-01, DE028282-01)
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1P50CA261605-01)
Colorado University | UC Denver | Colorado Clinical and Translational Sciences Institute (Pilot Grant Award)
- License Information
-
More Information
Article History
Received: 14 March 2022
Accepted: 2 November 2022
First Online: 16 November 2022
Change Date: 10 October 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-024-52861-x
Competing interests
: Dr. Karam receives clinical funding from Genentech and Ionis that does not relate to this work. She receives clinical trial funding from AstraZeneca, a part of which is included in this manuscript. She also receives preclinical research funding from Roche for work related to the anti-CD25 antibody, which is utilized as immunotherapy in this manuscript. The remaining authors declare no competing interests.
